Investment Thesis
Bluejay Diagnostics is an early-stage medical device company with minimal revenue ($249K) and severe burn rate (-$1.6M operating cash flow), limiting cash runway to approximately 2-3 years. Despite impressive 168% revenue growth and 19.6% gross margins, operating losses of -$1.9M on negligible sales and negative cash flow demonstrate the company cannot sustain operations without significant capital raise or rapid scaling.
Strengths
- Strong revenue growth momentum (168% YoY)
- Healthy gross margin (19.6%) indicates viable product economics
- Adequate liquidity (2.81x current ratio, $3.7M cash) provides near-term runway
Risks
- Critical cash burn: -$1.6M operating cash flow on $249K revenue; 3-year runway at current burn
- Extreme operating leverage problem: -$1.95M operating loss on minimal revenue signals massive cost structure relative to scale
- No clear path to profitability with negative FCF despite revenue growth; operating expenses consuming 8x quarterly revenue
Key Metrics to Watch
- Quarterly revenue absolute levels and growth sustainability (current $249K base too small)
- Operating cash flow trend and monthly burn rate in relation to cash balance
- Gross margin maintenance as revenue scales and whether OpEx can be controlled
Financial Metrics
Revenue
249.0K
Net Income
-1.9M
EPS (Diluted)
$-1.95
Free Cash Flow
-1.6M
Total Assets
5.6M
Cash
3.7M
Profitability Ratios
Gross Margin
19.6%
Operating Margin
-778.5%
Net Margin
-770.7%
ROE
-45.9%
ROA
-34.3%
FCF Margin
-645.8%
Balance Sheet & Liquidity
Current Ratio
2.81x
Quick Ratio
2.33x
Debt/Equity
0.00x
Debt/Assets
25.3%
Interest Coverage
-2.40x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-14T08:01:15.542181 |
Data as of: 2026-03-31 |
Powered by Claude AI